LL-37: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 23 sources cited

Overview

LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid peptide cleaved from the precursor protein hCAP-18 by proteinase 3 in neutrophils. It serves as a critical component of the innate immune system, providing broad-spectrum antimicrobial defense against bacteria, viruses, fungi, and biofilms. Beyond direct killing, LL-37 modulates immune cell recruitment, wound healing, angiogenesis, and inflammation resolution. It is expressed in neutrophils, macrophages, epithelial cells, and keratinocytes, and its deficiency is associated with recurrent infections, chronic wounds, and immune dysfunction. LL-37 is emerging as one of the most important peptides in immunology and infectious disease research.

Mechanism of Action

LL-37 is an amphipathic alpha-helical peptide with a net positive charge (+6 at physiological pH) that underlies its multifaceted biological activities. Its antimicrobial mechanism involves electrostatic attraction to negatively charged bacterial membranes (composed of phosphatidylglycerol and lipopolysaccharide), followed by membrane insertion and disruption. LL-37 can operate through multiple membrane-disruption models: the barrel-stave model (forming transmembrane pores), the toroidal pore model (inducing curvature strain that creates lipidic pores), and the carpet model (coating the membrane surface until a critical concentration causes dissolution). The preference for microbial over mammalian cells arises from the difference in membrane composition — mammalian cell membranes are rich in neutral phosphatidylcholine and cholesterol, which bind LL-37 less readily. The selectivity is only partial: in laboratory tests LL-37 damaged human red blood cells and cultured human cells, and serum reduced its antibacterial effect. Beyond direct membrane disruption, LL-37 is a potent anti-biofilm agent. It prevents biofilm formation by Pseudomonas aeruginosa, Staphylococcus aureus (including MRSA), and other biofilm-forming organisms at sub-inhibitory concentrations. It decreases bacterial attachment, stimulates twitching motility, influences two quorum-sensing systems, and downregulates genes essential for biofilm development. This anti-biofilm activity is particularly significant because biofilms are responsible for 80% of chronic infections and are 100–1,000x more resistant to conventional antibiotics. LL-37's immunomodulatory functions are equally important. It serves as an alarmin — signaling danger and recruiting immune cells to sites of infection or tissue damage. It chemoattracts neutrophils, monocytes, and T-cells through formyl peptide receptor-like 1 (FPRL1/FPR2) activation. Its effects on macrophages are mixed: in one study it reduced TNF-α and nitric oxide production by M1 macrophages without impairing their ability to engulf and kill bacteria, while in another it steered human monocytes toward macrophages with a pro-inflammatory signature. LL-37 neutralizes lipopolysaccharide (LPS/endotoxin) by direct binding; in rat models of gram-negative sepsis, intravenous LL-37 lowered plasma endotoxin and TNF-α and reduced deaths. In wound healing, LL-37 promotes re-epithelialization through EGFR transactivation, stimulates angiogenesis through VEGF induction and direct endothelial cell activation via FPRL1, and increases keratinocyte and fibroblast migration to wound sites. It also promotes wound closure through activation of P2X7 receptors and downstream MAPK signaling. LL-37 has antiviral activity against influenza, HIV, herpes simplex virus, and respiratory syncytial virus — primarily through direct virion disruption and enhancement of antiviral interferon responses. It activates plasmacytoid dendritic cells to produce type I interferons (IFN-α, IFN-β) through TLR9-dependent mechanisms, bridging innate and adaptive antiviral immunity.

LL-37 Benefits: What the Research Shows

  • Zanetti (2004) published a comprehensive review in Journal of Leukocyte Biology establishing cathelicidins as multifunctional host defense peptides with antimicrobial, immunomodulatory, and wound-healing properties
  • Overhage et al. (2008) demonstrated in Infection and Immunity that LL-37 inhibits Pseudomonas aeruginosa biofilm formation in vitro at 0.5 μg/mL, far below the 64 μg/mL needed to inhibit growth, by decreasing bacterial attachment, stimulating twitching motility, and influencing quorum sensing
  • An observation study found that patients with morbus Kostmann (severe congenital neutropenia) lacked LL-37 in their neutrophils, plasma and saliva and had severe periodontal disease, except for one patient whose LL-37 was restored after bone-marrow transplantation (Lancet, 2002)
  • Vitamin D induces the cathelicidin gene through a vitamin D response element. In a meta-analysis of 25 RCTs, vitamin D supplementation lowered the odds of acute respiratory infection by 12% (adjusted odds ratio 0.88; BMJ, 2017), but a 2025 update with more trials found no statistically significant overall effect. Neither analysis measured LL-37
  • Research by Lande et al. (2007) in Nature showed LL-37 complexed with self-DNA activates plasmacytoid dendritic cells through TLR9, connecting LL-37 to both antimicrobial defense and autoimmune pathology (psoriasis)
  • Studies demonstrated LL-37 neutralizes LPS endotoxin activity, preventing TNF-α release from macrophages and protecting against septic shock in animal models
  • Cell studies showed LL-37 induces keratinocyte migration through EGFR transactivation (Journal of Immunology, 2005). In human trials of topical LL-37 for hard-to-heal venous leg ulcers, a 34-patient first-in-man trial found faster healing at the two lower doses (2014), but a 148-patient phase IIb trial found no significant improvement over placebo in the full study population (2021)
  • In a mouse model of MRSA-infected wounds, LL-37 given topically and by injection improved re-epithelialization, granulation tissue and angiogenesis (2021). Clinical MRSA strains, however, are more resistant to LL-37 than methicillin-susceptible strains (2008)
  • In mice infected with influenza A, LL-37 reduced disease severity and viral replication to a similar extent as zanamivir and lowered pro-inflammatory cytokines in the lung; the peptide appeared to act directly on the virus particle (PLoS One, 2011)

LL-37 Dosage

  • Subcutaneous injection for systemic immune support: 50–100 mcg daily or every other day
  • Anti-biofilm/chronic infection protocol: 100 mcg subcutaneous daily for 4–8 weeks
  • Wound healing: 50–100 mcg injected locally around wound margins, or topical application in a suitable vehicle
  • Respiratory infection support: 50–100 mcg subcutaneous daily during acute illness, for 7–14 days
  • Oral/sublingual for gut immune support: 100–200 mcg daily
  • Cycle: 4–8 weeks on for acute indications; can be used intermittently during infection seasons
  • Prophylactic immune support: 50 mcg every other day during cold/flu season
  • Can be nebulized for direct respiratory delivery in specific clinical protocols (under medical guidance)
  • Start at lower doses (50 mcg) and titrate up based on response and tolerance
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

LL-37 Side Effects & Safety

Known Side Effects

  • Injection site reactions: redness, swelling, warmth, and mild pain (common — LL-37 activates local immune cells, causing a controlled inflammatory response)
  • Transient flu-like symptoms possible during first 1–2 days as immune system is activated (low-grade temperature, mild fatigue)
  • Mild histamine-like response: flushing, urticaria at injection site (LL-37 activates mast cells)
  • Herxheimer-like reaction possible when treating chronic infections or biofilm — temporary worsening of symptoms as microbial die-off releases toxins
  • Theoretical concern: LL-37 overexpression is implicated in psoriasis pathogenesis — those with psoriasis should use cautiously
  • Rare: nausea with higher doses

Safety Profile

LL-37 is an endogenous human peptide produced naturally by immune cells, epithelial surfaces, and skin — it is a fundamental component of human immunity. That does not establish that dosing with it is safe: the FDA says it lacks sufficient safety information to know whether LL-37 would cause harm when administered to humans, and notes nonclinical findings suggesting detrimental effects on male reproduction and that it can be protumorigenic in some tissues. The primary safety consideration is the psoriasis connection: LL-37 forms complexes with self-DNA that can activate autoimmune pathways in genetically susceptible individuals. Those with active psoriasis or a strong family history should exercise caution and discuss with their physician. Topical LL-37 was well tolerated in venous leg ulcer trials, but there are few human data on injected LL-37; in a phase 1 melanoma trial of injections into tumors, one reported patient developed widespread inflammatory skin lesions that resolved after treatment stopped. Its selectivity for microbes is only partial, since LL-37 damaged human red blood cells and cultured cells in laboratory tests. Local injection site reactions are commonly reported by users. Contraindicated in active psoriasis flares, known autoimmune conditions involving LL-37 pathology, and pregnancy (insufficient data). Drug interactions: may synergize with conventional antibiotics (potential to use lower antibiotic doses). Self-injection for immune support has not been studied in humans.

What to Expect

This timeline comes from user reports; injected LL-37 has not been studied in humans for immune support. Week 1: Injection site may show redness and mild swelling (expected immune activation). Subtle improvements in energy and well-being as immune function is supported. Those with chronic/subclinical infections may experience a Herxheimer-like reaction (temporary symptom flare as microbes are killed). Weeks 2–3: Immune function noticeably improved — fewer cold/flu symptoms if used during infection season. Chronic wounds show improved healing trajectory. Biofilm-associated symptoms (sinus infections, skin infections, gut dysbiosis) begin to improve. Weeks 4–6: Chronic infections show significant improvement. Wound healing is substantially accelerated. Recurrent infection frequency decreases. Systemic inflammation markers may improve. Weeks 7–12: Maximum antimicrobial and immunomodulatory benefits. Chronic biofilm-mediated infections that were previously treatment-resistant may finally resolve. Immune resilience is established. Users report that benefits persist after discontinuation, though ongoing immune support may be needed for immunocompromised individuals.

Common Stacks

Storage & Handling

LL-37 requires careful storage due to its larger size (37 amino acids) and amphipathic nature. Store lyophilized at -20°C for up to 18 months or 2–8°C for up to 6 months. Reconstitute with sterile bacteriostatic water — add water slowly along the vial wall, do not shake. Once reconstituted, store at 2–8°C and use within 2–3 weeks. LL-37 can aggregate and lose activity if mishandled. Aliquoting into single-use portions and freezing at -20°C can extend usable life. Solution should be clear; discard if cloudy or precipitate forms. Protect from repeated freeze-thaw cycles.

Pricing & Available Variants

$150price range
10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Grönberg A, Mahlapuu M, Ståhle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014.
  2. Mahlapuu M, Sidorowicz A, Mikosinski J, et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen. 2021.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
  4. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004.
  5. Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001.
  6. Overhage J, Campisano A, Bains M, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008.
  7. De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000.
  8. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007.
  9. Pütsep K, Carlsson G, Boman HG, et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet. 2002.
  10. Tokumaru S, Sayama K, Shirakata Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005.
  11. Carretero M, Escámez MJ, García M, et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol. 2008.
  12. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003.
  13. Cirioni O, Giacometti A, Ghiselli R, et al. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother. 2006.
  14. Ciornei CD, Sigurdardóttir T, Schmidtchen A, et al. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chemother. 2005.
  15. Brown KL, Poon GF, Birkenhead D, et al. Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J Immunol. 2011.
  16. van der Does AM, Beekhuizen H, Ravensbergen B, et al. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol. 2010.
  17. Barlow PG, Svoboda P, Mackellar A, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2011.
  18. Simonetti O, Cirioni O, Goteri G, et al. Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model. Antibiotics (Basel). 2021.
  19. Ouhara K, Komatsuzawa H, Kawai T, et al. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus. J Antimicrob Chemother. 2008.
  20. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017.
  21. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data. Lancet Diabetes Endocrinol. 2025.
  22. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004.
  23. Dolkar T, Trinidad CM, Nelson KC, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018.

Related Peptides

Track LL-37 in Your Protocol

Log your LL-37 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free